Galectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic disease and cancer. The company has market cap of $156.84 million. The companyÂ’s lead product candidate includes galectin-3 inhibitor , a galactoarabino-rhamnogalacturonan polysaccharide polymer for the treatment of liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis patients, as well as for the treatment of cancer. It currently has negative earnings. It also engages in developing GM-CT-01, which is in pre-clinical development state for the treatment of cardiac and vascular fibrosis, as well as focuses on developing GR-MD-02 for the treatment of psoriasis.
The Ultimate Software Group, Inc. (ULTI) formed inverse H&S with $255.44 target or 4.00% above today’s $245.62 share price. The Ultimate Software Group, Inc. (ULTI) has $7.34 billion valuation. The stock decreased 0.54% or $1.34 during the last trading session, reaching $245.62. About 262,475 shares traded. The Ultimate Software Group, Inc. (NASDAQ:ULTI) has risen 10.74% since February 20, 2017 and is uptrending. It has underperformed by 5.96% the S&P500.
Among 27 analysts covering Ultimate Software (NASDAQ:ULTI), 19 have Buy rating, 1 Sell and 7 Hold. Therefore 70% are positive. Ultimate Software had 67 analyst reports since October 22, 2015 according to SRatingsIntel. The rating was maintained by Stifel Nicolaus on Wednesday, October 28 with “Buy”. KeyBanc Capital Markets maintained the shares of ULTI in report on Sunday, June 25 with “Buy” rating. The stock has “Overweight” rating by Piper Jaffray on Wednesday, June 1. The firm earned “Mkt Perform” rating on Wednesday, October 28 by FBR Capital. On Tuesday, January 16 the stock rating was maintained by Piper Jaffray with “Buy”. Guggenheim maintained the stock with “Buy” rating in Wednesday, February 7 report. The rating was maintained by Guggenheim with “Buy” on Wednesday, January 10. The stock of The Ultimate Software Group, Inc. (NASDAQ:ULTI) earned “Buy” rating by Wedbush on Wednesday, February 7. Stephens maintained the stock with “Hold” rating in Wednesday, August 2 report. The rating was maintained by Robert W. Baird with “Hold” on Monday, September 11.
Since February 8, 2018, it had 0 buys, and 6 sales for $52.94 million activity. $1.61M worth of The Ultimate Software Group, Inc. (NASDAQ:ULTI) was sold by Phenicie John C on Friday, February 9. Shares for $677,298 were sold by Swick Gregory on Friday, February 9. Rogers Adam had sold 3,563 shares worth $813,775. $18.71 million worth of The Ultimate Software Group, Inc. (NASDAQ:ULTI) was sold by SCHERR MARC D on Thursday, February 8. DAUERMAN MITCHELL K sold $6.32M worth of stock. SCHERR SCOTT had sold 110,522 shares worth $24.82 million on Thursday, February 8.
Investors sentiment decreased to 1.05 in Q3 2017. Its down 0.02, from 1.07 in 2017Q2. It fall, as 21 investors sold The Ultimate Software Group, Inc. shares while 104 reduced holdings. 52 funds opened positions while 79 raised stakes. 32.11 million shares or 2.37% less from 32.89 million shares in 2017Q2 were reported. Aperio Group Ltd Limited Liability Company reported 20,507 shares. Bluecrest Cap Ltd invested in 6,151 shares or 0.05% of the stock. Eulav Asset Mgmt invested in 115,800 shares. Moreover, Brown Advisory has 0.11% invested in The Ultimate Software Group, Inc. (NASDAQ:ULTI) for 171,623 shares. Prudential Financial accumulated 0.01% or 18,301 shares. Brown Capital Mngmt Limited invested 0.01% in The Ultimate Software Group, Inc. (NASDAQ:ULTI). Sei Invs Communications reported 0.04% of its portfolio in The Ultimate Software Group, Inc. (NASDAQ:ULTI). Ftb Advsrs reported 108 shares. Louisiana State Employees Retirement has invested 0.07% in The Ultimate Software Group, Inc. (NASDAQ:ULTI). Summit Creek Advsr, a Minnesota-based fund reported 51,735 shares. Rainier Invest Mgmt Limited Liability Corporation has invested 0.16% in The Ultimate Software Group, Inc. (NASDAQ:ULTI). State Of Wisconsin Invest Board reported 0% of its portfolio in The Ultimate Software Group, Inc. (NASDAQ:ULTI). The Virginia-based Alexandria Ltd Co has invested 0% in The Ultimate Software Group, Inc. (NASDAQ:ULTI). Hhr Asset Mngmt Limited Co invested in 394,388 shares or 3.9% of the stock. Mason Street Advsr Limited Liability Company accumulated 14,064 shares.
Benchmark Capital Advisors holds 0.32% of its portfolio in Galectin Therapeutics, Inc. for 194,200 shares. Courage Capital Management Llc owns 130,000 shares or 0.19% of their US portfolio. Moreover, Cutter & Co Brokerage Inc. has 0.05% invested in the company for 54,600 shares. The Missouri-based Buckingham Asset Management Llc has invested 0.03% in the stock. D.A. Davidson & Co., a Montana-based fund reported 690,960 shares.
Ratings analysis reveals 0 of Galectin Therapeutics’s analysts are positive. Out of 3 Wall Street analysts rating Galectin Therapeutics, 0 give it “Buy”, 1 “Sell” rating, while 2 recommend “Hold”. The lowest target is $1.5 while the high is $2.0. The stock’s average target of $1.75 is -59.68% below today’s ($4.34) share price. GALT was included in 3 notes of analysts from September 28, 2016. The firm earned “Neutral” rating on Thursday, September 29 by H.C. Wainwright. The stock has “Sell” rating by Roth Capital on Wednesday, September 28. The rating was downgraded by FBR Capital to “Mkt Perform” on Monday, October 3.
Since January 1, 0001, it had 2 insider purchases, and 2 selling transactions for $2.64 million activity.
Analysts await Galectin Therapeutics, Inc. (NASDAQ:GALT) to report earnings on March, 27. They expect $-0.11 EPS, up 15.38% or $0.02 from last year’s $-0.13 per share. After $-0.13 actual EPS reported by Galectin Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -15.38% EPS growth.